Introduction And Background
Intracranial metastatic melanoma is a devastating and common occurrence in patients with advanced melanoma. As of 2011, more than 40% of patients with metastatic melanoma experienced brain metastasis, and this number is increasing [1] [2] . Stereotactic radiosurgery (SRS) is a safe and effective modality for treating many types of primary and metastatic brain tumors and is commonly used for the treatment of melanoma brain metastasis. BRAF-V600E is the most common activating mutation found in melanoma. After the molecular diagnosis is established, targeted therapies (TTs) such as BRAF/mitogen-activated protein (MAP) kinase kinase (MEK) inhibitors (BRAFi/MEKi), which block the activated MAP-kinase cascade are employed [3] . Immunotherapeutics (IMTs) such as ipilimumab (anti-CTLA4 [cytotoxic Tlymphocyte associated protein 4] therapy) have yielded improved overall survival from metastatic melanoma (two large, phase III trials), and along with nivolumab/pembrolizumab (anti-PD1 [programmed cell death protein 1] therapy), comprise the cornerstone of current melanoma immunotherapy [4] [5] . Recently, phase II trials have begun investigating the effectiveness of IMTs with and without SRS [NCT02085070; NCT02374242; NCT02460068; NCT02320058]. Importantly, the optimal timing of combination systemic therapy and SRS is yet to be defined, particularly for IMTs, and preclinical studies suggest that concurrent therapy may be superior to staggered drug and SRS administration [6] . We undertook a systematic review of studies involving a window of concurrent systemic therapy within three months of SRS treatment, defined as administration of IMT or TT within three months of SRS, in an effort to better define the optimal timing.
Review Database review
Two separate reviewers performed Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA)-based systematic reviews of both Scopus and MEDLINE databases (October 2018) using "stereotactic radiosurgery" and "melanoma" as keywords. Articles were included if they examined the treatment of intracranial metastatic melanoma with SRS and BRAFi/MEKi inhibitors or immunotherapeutic checkpoint inhibitors (i.e., anti-PD1 and anti-CTLA4 monoclonal antibodies). Studies were included if they reported ≤30% of patients previously, or concurrently, treated with whole-brain radiotherapy. Critically, studies were included only if they described concurrent combinations of SRS and systemic therapies (i.e., systemic therapy within a three-month window before or after SRS treatment) ( Table 1) . Endpoints of interest included overall survival, local control, distant control, and treatment toxicities.
After a systematic review of the literature, five articles were included for qualitative analysis ( Figure 1 ). Hazard ratios (HRs) reported were transformed from failure to control, if necessary, using 1/HR. If a study presented both univariate and multivariate analyses of an outcome measure, the multivariate analysis was included in our qualitative assessment. 
Studies identified
The five retrospective cohort studies that met our inclusion criteria all provided only lowquality evidence with heterogeneous outcomes ( Table 1 ; GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria); therefore, a meta-analysis of the data was not possible [7] [8] [9] [10] [11] . A major source of heterogeneity in all studies of SRS and systemic therapies is the definition of "concurrent" therapy. To address this issue, we propose assessment during two key intervals: a four-week interval (concurrent therapy) and a three-month window (peri-SRS therapy). 
Results of Concurrent Immunotherapy and SRS
Concurrent therapy was generally favored for all reported outcomes. Possibly, the largest effect was on distant brain control combining IMT+SRS (HRs ≥2 for distant control in all but one case; Figure 2 ). Local control favored concurrent therapy, but this trend was obscured by unexpected differences in HRs for similar patient populations ( Figure 2 ) [9, 11] . Overall survival with concurrent IMT+SRS was also improved. Only Acharya et al. found a statistically insignificant decrease in HR for overall survival in patients receiving concurrent IMT and SRS ( Figure 2 ) [7] . There was no significant difference in toxicities between the SRS only and the SRS + IMT treatment groups ( Table 2 ). Regression or control of lesions outside of the initial radiation field, called the abscopal effect, may drive favorable outcomes for distant brain tumors in patients treated with concurrent IMT+SRS [12] [13] [14] . The abscopal effect is an immune system-mediated effect that requires T-cell effector function on tumor-associated neoantigens (TAAs) and immune-enhancing cytokine release in the tumor microenvironment. This may synergize with checkpoint inhibitors, releasing the brakes on antitumor immunity (Figure 3 ) [15] [16] [17] . The reactivation of innate immune-sensing and interferon responses in tumor cells, which is critical for antitumor immunity, is attributed to the expression of endogenous retroviral sequences and other genomic 'dark matter' after epigenetic therapies [18, [19] [20] [21] . Combining epigenetic, stereotactic radiosurgical, and immune-checkpoint therapies may hold great promise for patients with melanoma brain metastasis. 
FIGURE 2: Efficacy of concurrent immunotherapy and SRS for

Results of BRAFi/MEKi and Stereotactic Radiosurgery
Inhibitors of the MAP-kinase pathway have become a mainstay of melanoma treatment, particularly in the setting of activating BRAF mutations. Importantly, patients treated with targeted therapies after molecular diagnosis have significantly better progression-free and overall survival than patients treated with dacarbazine or placebo [22] [23] [24] [25] . There is little information regarding the optimal timing of targeted therapy dosage relative to SRS, but many oncological teams withhold targeted therapies for 3-5 days surrounding SRS treatment. Studies that report the efficacy of SRS and targeted therapies are summarized in Table 4 , including reason for exclusion from our systematic review [26] [27] [28] [29] [30] . Improved brain tumor control and overall survival evident in concurrent or post-SRS ( Figure 4 ; Table 3 ) BRAFi/MEKi may reflect increased accessibility of these therapies to the brain tumor environment after SRS, yet concurrent vemurafenib or dabrafenib and SRS has been reported to increase risk for radiation necrosis and Grade ≥3 adverse events, especially skin toxicities [30] [31] [32] . Of interest, there were no significant differences in toxicities in patients receiving concurrent BRAFi/MEKi+SRS versus SRS alone, indicating that a small pause directly surrounding SRS may be sufficient to ensure patient safety ( Table 3 ). 
FIGURE 4: Efficacy of concurrent targeted therapy and SRS for melanoma brain metastases
Conclusions
Five studies in the literature explore concurrent timing of stereotactic radiosurgery and immunotherapy or targeted therapies for the treatment of intracranial metastatic melanomas. Additional temporally specific studies are needed, but more vital is the need for well-designed prospective trials, several of which are under way [NCT02085070; NCT02374242; NCT02460068; NCT02320058]. Future studies should report outcomes based on a four-week window (concurrent SRS) or a three-month window (peri-SRS).
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